India-based Apollo Hospitals Enterprise has signed a term sheet with Ion Beam Applications (IBA) to procure one ProteusONE compact proton therapy solution, with the option to procure a second unit.
This move is set to enhance the accessibility of proton therapy in the country.
Go deeper with GlobalData
The ProteusONE systems feature a compact design and can be upgraded over time. Apollo Hospitals anticipates beginning patient treatments using the systems by 2028.
Pending regulatory approval, these systems will also feature DynamicARC beam delivery capabilities.
The cost of each ProteusONE system, including a multi-year maintenance contract, is estimated to be between €35m and €45m ($37.42m and $48.05m).
This agreement builds upon the existing partnership between Apollo Hospitals AHEL and IBA, which began in 2013 when AHEL introduced the first proton beam therapy in the country with the system.
Apollo Hospitals founder and chairman Dr Prathap Reddy said: “The addition of ProteusONE further cements our position as a global leader in proton beam therapy treatments, enabling us to deliver superior clinical outcomes and improve the quality of life for cancer patients in India and worldwide.”
In August 2022, the two companies signed a partnership agreement for proton therapy training and education programmes for IBA customers across Asia.
IBA CEO Olivier Legrain said: “These contracts expand upon the close relationship we have built for more than a decade with Apollo Hospitals. Having an existing customer reaffirm their confidence in our solutions demonstrates not only the reliability and superiority of the IBA portfolio but also highlights the level of excellence of the services we deliver.”
In April 2024, Apollo Hospitals announced plans to invest approximately $360m to support both organic growth and strategic acquisitions, with a significant portion funded by a deal with private equity firm Advent International.
